Martin J B Van Den Bent

List of Publications by Year
in descending order

458	71,786	1371 108	642 256
papers	citations	h-index	g-index

471	471	471	40774
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine, 2005, 352, 987-996.	27.0	17,395
2	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology, The, 2009, 10, 459-466.	10.7	6,451
3	Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. Journal of Clinical Oncology, 2010, 28, 1963-1972.	1.6	3,222
4	Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology, 2013, 31, 344-350.	1.6	1,003
5	Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncology, The, 2008, 9, 453-461.	10.7	990
6	Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet, The, 2005, 366, 985-990.	13.7	880
7	Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma. Journal of Clinical Oncology, 2002, 20, 2076-2084.	1.6	826
8	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nature Reviews Clinical Oncology, 2021, 18, 170-186.	27.6	826
9	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncology, The, 2017, 18, e315-e329.	10.7	816
10	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2014, 15, 1100-1108.	10.7	800
11	Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma. Journal of Clinical Oncology, 2005, 23, 5034-5043.	1.6	729
12	Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncology, The, 2015, 16, e270-e278.	10.7	711
13	Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial. Journal of Clinical Oncology, 2006, 24, 2715-2722.	1.6	690
14	Lomustine and Bevacizumab in Progressive Glioblastoma. New England Journal of Medicine, 2017, 377, 1954-1963.	27.0	670
15	EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncology, The, 2014, 15, e395-e403.	10.7	647
16	MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nature Reviews Neurology, 2010, 6, 39-51.	10.1	644
17	Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncology, The, 2014, 15, 943-953.	10.7	639
18	Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology. Cancer Research, 2009, 69, 9065-9072.	0.9	575

#	Article	IF	Citations
19	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113.	1.2	543
20	High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, iii93-iii101.	1.2	532
21	Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncology, The, 2011, 12, 583-593.	10.7	508
22	Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034. Journal of Clinical Oncology, 2009, 27, 1268-1274.	1.6	503
23	Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain, 2003, 126, 1409-1418.	7.6	497
24	Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma. Journal of Clinical Oncology, 2013, 31, 3212-3218.	1.6	489
25	Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncology, The, 2008, 9, 29-38.	10.7	487
26	MGMT testingâ€"the challenges for biomarker-based glioma treatment. Nature Reviews Neurology, 2014, 10, 372-385.	10.1	454
27	Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma. Journal of Clinical Oncology, 2010, 28, 1168-1174.	1.6	450
28	Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial. Journal of Clinical Oncology, 2006, 24, 2563-2569.	1.6	447
29	Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinicianâ€™s perspective. Acta Neuropathologica, 2010, 120, 297-304.	7.7	439
30	Incidence of early pseudoâ€progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer, 2008, 113, 405-410.	4.1	403
31	Cyclosporine neurotoxicity: a review. Journal of Neurology, 1999, 246, 339-346.	3.6	402
32	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncology, The, 2016, 17, 1521-1532.	10.7	396
33	Molecular targeted therapy of glioblastoma. Cancer Treatment Reviews, 2019, 80, 101896.	7.7	386
34	IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research, 2010, 16, 1597-1604.	7.0	364
35	cIMPACTâ€NOW update 6: new entity and diagnostic principle recommendations of the cIMPACTâ€Utrecht meeting on future CNS tumor classification and grading. Brain Pathology, 2020, 30, 844-856.	4.1	363
36	Changing Paradigmsâ€"An Update on the Multidisciplinary Management of Malignant Glioma. Oncologist, 2006, 11, 165-180.	3.7	357

#	Article	IF	Citations
37	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-Oncology, 2015, 17, 1188-98.	1.2	346
38	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathologica, 2020, 139, 603-608.	7.7	344
39	Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurology, The, 2010, 9, 906-920.	10.2	335
40	Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology, 2004, 63, 535-537.	1.1	334
41	Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood, 2010, 115, 5005-5011.	1.4	325
42	Pseudoprogression and pseudoresponse in the treatment of gliomas. Current Opinion in Neurology, 2009, 22, 633-638.	3.6	312
43	High-Dose Methotrexate-Based Chemotherapy Followed by Consolidating Radiotherapy in Nonâ€“AIDS-Related Primary Central Nervous System Lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. Journal of Clinical Oncology, 2003, 21, 4483-4488.	1.6	308
44	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet, The, 2017, 390, 1645-1653.	13.7	307
45	Response Assessment in Neuro-Oncology Clinical Trials. Journal of Clinical Oncology, 2017, 35, 2439-2449.	1.6	306
46	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathologica, 2018, 136, 153-166.	7.7	298
47	Cognitive Rehabilitation in Patients With Gliomas: A Randomized, Controlled Trial. Journal of Clinical Oncology, 2009, 27, 3712-3722.	1.6	294
48	An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. European Journal of Cancer, 2010, 46, 1033-1040.	2.8	293
49	Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. Journal of Clinical Oncology, 2003, 21, 2525-2528.	1.6	288
50	Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncology, The, 2005, 6, 937-944.	10.7	288
51	cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathologica, 2018, 135, 639-642.	7.7	281
52	MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathologica, 2012, 124, 547-560.	7.7	274
53	Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. Lancet Oncology, The, 2019, 20, 728-740.	10.7	271
54	Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology, 2011, 77, 1156-1164.	1.1	267

#	Article	IF	Citations
55	Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. Journal of Clinical Oncology, 2022, 40, 492-516.	1.6	261
56	The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. European Journal of Cancer, 2004, 40, 2726-2733.	2.8	253
57	MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology, 2009, 27, 5881-5886.	1.6	232
58	End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria. Journal of Clinical Oncology, 2009, 27, 2905-2908.	1.6	229
59	Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. Journal of Neurology, 2002, 249, 745-753.	3.6	224
60	The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro-Oncology, 2018, 20, 103-112.	1.2	220
61	CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology, 2007, 68, 1674-1679.	1.1	213
62	Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. British Journal of Cancer, 2003, 88, 1199-1206.	6.4	204
63	Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas. Neurosurgery, 2012, 70, 234-244.	1.1	204
64	Pseudoprogression of brain tumors. Journal of Magnetic Resonance Imaging, 2018, 48, 571-589.	3.4	199
65	Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. Journal of Clinical Oncology, 2008, 26, 4659-4665.	1.6	194
66	Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?. Lancet Oncology, The, 2011, 12, 83-91.	10.7	188
67	An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. Journal of Neurology, 2006, 253, 16-20.	3.6	186
68	Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer, 2003, 97, 1276-1284.	4.1	184
69	Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Neurology, 1998, 51, 1140-1145.	1.1	180
70	IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology, 2009, 73, 1792-1795.	1.1	176
71	Optimal role of temozolomide in the treatment of malignant gliomas. Current Neurology and Neuroscience Reports, 2005, 5, 198-206.	4.2	168
72	Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochirurgica, 2011, 153, 1211-1218.	1.7	168

#	Article	IF	Citations
73	Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncology, The, 2022, 23, 53-64.	10.7	165
74	Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncology, The, 2019, 20, 216-228.	10.7	163
75	Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathologica, 2015, 129, 809-827.	7.7	162
76	New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. European Journal of Cancer, 2012, 48, 1176-1184.	2.8	161
77	Imaging Correlates of Adult Glioma Genotypes. Radiology, 2017, 284, 316-331.	7.3	160
78	Diagnostic value of OCT3/4 for preâ€invasive and invasive testicular germ cell tumours. Journal of Pathology, 2005, 206, 242-249.	4.5	158
79	Leptomeningeal metastases: a RANO proposal for response criteria. Neuro-Oncology, 2017, 19, now183.	1.2	157
80	Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro-Oncology, 2012, 14, iv100-iv108.	1.2	154
81	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro-Oncology, 2023, 25, 123-134.	1.2	150
82	Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Annals of Oncology, 2003, 14, 599-602.	1.2	149
83	cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). Acta Neuropathologica, 2018, 135, 481-484.	7.7	145
84	Panel Review of Anaplastic Oligodendroglioma From European Organization for Research and Treatment of Cancer Trial 26951. Journal of Neuropathology and Experimental Neurology, 2007, 66, 545-551.	1.7	143
85	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro-Oncology, 2016, 18, 388-400.	1.2	143
86	Diffuse Infiltrating Oligodendroglioma and Astrocytoma. Journal of Clinical Oncology, 2017, 35, 2394-2401.	1.6	142
87	Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro-Oncology, 2014, 16, 1176-1185.	1.2	141
88	Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro-Oncology, 2020, 22, 515-523.	1.2	140
89	The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Neuro-Oncology, 2018, 20, 1393-1399.	1.2	139
90	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro-Oncology, 2017, 19, 625-635.	1.2	137

#	Article	IF	Citations
91	Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Annals of Oncology, 2011, 22, 2107-2112.	1.2	136
92	Identification of delta/notchâ€like epidermal growth factorâ€related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Annals of Neurology, 2012, 71, 815-824.	5.3	136
93	Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro-Oncology, 2015, 17, 935-941.	1.2	136
94	Cognitive functioning and quality of life in long-term adult survivors of bone marrow transplantation. Cancer, 2002, 95, 183-192.	4.1	133
95	Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology, 2004, 62, 544-547.	1.1	133
96	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC) Tj ETQq0 0 0 rgBT /Overlock 10 Oncology, The, 2021, 22, 813-823.	10.7	132
97	Optimal management of elderly patients with glioblastoma. Cancer Treatment Reviews, 2013, 39, 350-357.	7.7	131
98	Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. Neuro-Oncology, 2020, 22, 757-772.	1.2	131
99	Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathologica, 2010, 120, 585-592.	7.7	127
100	INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro-Oncology, 2020, 22, 684-693.	1.2	126
101	1H chemical shift imaging reveals loss of brain tumor choline signal after administration of Gd-contrast. Magnetic Resonance in Medicine, 1997, 37, 222-225.	3.0	125
102	Outcome and complications of epidural analgesia in patients with chronic cancer pain. Cancer, 1998, 83, 2015-2022.	4.1	124
103	Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer, 2005, 103, 802-809.	4.1	123
104	Peripheral neurotoxicity induced by docetaxel. Neurology, 1996, 46, 104-108.	1.1	119
105	Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncology, The, 2013, 14, e407-e416.	10.7	119
106	Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. Neuro-Oncology, 2014, 16, 1570-1574.	1.2	119
107	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncology, The, 2013, 14, e396-e406.	10.7	116
108	Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncology, The, 2020, 21, e305-e316.	10.7	115

#	Article	IF	Citations
109	Neurological adverse effects caused by cytotoxic and targeted therapies. Nature Reviews Clinical Oncology, 2009, 6, 596-603.	27.6	114
110	Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. Neuro-Oncology, 2019, 21, 571-584.	1.2	114
111	Bevacizumab and Recurrent Malignant Gliomas: A European Perspective. Journal of Clinical Oncology, 2010, 28, e188-e189.	1.6	112
112	1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. European Journal of Cancer, 2006, 42, 2499-2503.	2.8	111
113	The role of chemotherapy in brain metastases. European Journal of Cancer, 2003, 39, 2114-2120.	2.8	110
114	Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. Neuro-Oncology, 2020, 22, 1262-1275.	1.2	109
115	PCV chemotherapy for recurrent glioblastoma multiforme. Neurology, 2001, 56, 118-120.	1.1	108
116	Recent developments in the use of chemotherapy in brain tumours. European Journal of Cancer, 2006, 42, 582-588.	2.8	108
117	Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. Cancer Chemotherapy and Pharmacology, 2017, 80, 1209-1217.	2.3	108
118	A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951. Clinical Cancer Research, 2011, 17, 7148-7155.	7.0	107
119	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro-Oncology, 2017, 19, 1119-1126.	1.2	107
120	MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951. Clinical Cancer Research, 2013, 19, 5513-5522.	7.0	106
121	Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. British Journal of Cancer, 2001, 84, 157-163.	6.4	105
122	Clinical trial end points for high-grade glioma: the evolving landscape. Neuro-Oncology, 2011, 13, 353-361.	1.2	105
123	Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). Clinical Cancer Research, 2016, 22, 4797-4806.	7.0	105
124	Gene Expression Profiles Associated with Treatment Response in Oligodendrogliomas. Cancer Research, 2005, 65, 11335-11344.	0.9	102
125	Health-Related Quality of Life in Patients Treated for Anaplastic Oligodendroglioma With Adjuvant Chemotherapy: Results of a European Organisation for Research and Treatment of Cancer Randomized Clinical Trial. Journal of Clinical Oncology, 2007, 25, 5723-5730.	1.6	100
126	A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. Neuro-Oncology, 2017, 19, 614-624.	1.2	100

#	Article	IF	Citations
127	Intrinsic Molecular Subtypes of Glioma Are Prognostic and Predict Benefit From Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Combination With Other Prognostic Factors in Anaplastic Oligodendroglial Brain Tumors: A Report From EORTC Study 26951. Journal of Clinical Oncology, 2013, 31, 328-336.	1.6	99
128	Identification of Tumor-Related Proteins by Proteomic Analysis of Cerebrospinal Fluid from Patients with Primary Brain Tumors. Journal of Neuropathology and Experimental Neurology, 2003, 62, 855-862.	1.7	98
129	Evidence-based recommendations on categories for extent of resection in diffuse glioma. European Journal of Cancer, 2021, 149, 23-33.	2.8	97
130	The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. British Journal of Cancer, 2007, 97, 302-307.	6.4	94
131	Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. Neuro-Oncology, 2017, 19, 12-21.	1.2	94
132	Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial. Cancer Research, 2016, 76, 525-534.	0.9	93
133	Segregation of non-p.R132H mutations inIDH1in distinct molecular subtypes of glioma. Human Mutation, 2010, 31, E1186-E1199.	2.5	90
134	Antibodyâ€“drug conjugates in glioblastoma therapy: the right drugs to the right cells. Nature Reviews Clinical Oncology, 2017, 14, 695-707.	27.6	90
135	The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. Neuro-Oncology, 2019, 21, 648-658.	1.2	90
136	Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology, 2001, 57, 340-342.	1.1	89
137	New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. Neuro-Oncology, 2013, 15, 1568-1579.	1.2	88
138	Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathologica, 2017, 134, 957-959.	7.7	87
139	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncology, The, 2018, 19, e20-e32.	10.7	87
140	Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Annals of Oncology, 1997, 8, 187-190.	1.2	86
141	Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology, 2004, 63, 904-906.	1.1	85
142	Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients withEGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. Neuro-Oncology, 2019, 21, 106-114.	1.2	84
143	Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. Journal of Clinical Oncology, 2020, 38, 81-99.	1.6	84
144	Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas. Cancer, 2006, 106, 388-395.	4.1	83

#	Article	IF	Citations
145	Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of Neuro-Oncology, 2014, 116, 161-168.	2.9	83
146	Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. Genome Biology, 2015, 16, 16.	8.8	82
147	Identification of Differentially Regulated Splice Variants and Novel Exons in Glial Brain Tumors Using Exon Expression Arrays. Cancer Research, 2007, 67, 5635-5642.	0.9	81
148	Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro-Oncology, 2017, 19, now257.	1.2	80
149	Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. Lancet Oncology, The, 2018, 19, 1170-1179.	10.7	80
150	How we treat patients with leptomeningeal metastases. ESMO Open, 2019, 4, e000507.	4.5	79
151	Leptomeningeal metastasis after surgical resection of brain metastases. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 66, 225-227.	1.9	77
152	Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathologica, 2012, 123, 841-852.	7.7	77
153	â€œReal worldâ€•use of a highly reliable imaging sign: â€œT2-FLAIR mismatchâ€•for identification of IDH mutant astrocytomas. Neuro-Oncology, 2020, 22, 936-943.	1.2	77
154	Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 36-40.	1.9	76
155	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathologica, 2018, 135, 601-615.	7.7	76
156	A novel tool to analyze MRI recurrence patterns in glioblastoma. Neuro-Oncology, 2008, 10, 1019-1024.	1.2	74
157	Anterior Cervical Discectomy With or Without Fusion With Acrylate. Spine, 1996, 21, 834-839.	2.0	72
158	Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro-Oncology, 2009, 11, 737-746.	1.2	71
159	EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. European Journal of Cancer, 2010, 46, 348-354.	2.8	71
160	Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm. Clinical Cancer Research, 2019, 25, 7455-7462.	7.0	70
161	Oligodendrogliomas: Molecular Biology and Treatment. Oncologist, 2009, 14, 155-163.	3.7	68
162	Paclitaxel (Taxol) induces cumulative mild neurotoxicity. European Journal of Cancer, 1994, 30, 1074-1077.	2.8	67

#	Article	IF	Citations
163	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. Journal of Clinical Oncology, 2022, 40, 403-426.	1.6	67
164	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. Neuro-Oncology, 2019, 21, 837-853.	1.2	66
165	Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.. Journal of Clinical Oncology, 1997, 15, 1071-1079.	1.6	64
166	Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro-Oncology, 2003, 5, 128-138.	1.2	64
167	Oligodendroglioma. Critical Reviews in Oncology/Hematology, 2008, 66, 262-272.	4.4	64
168	Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing. Journal of Molecular Diagnostics, 2016, 18, 775-786.	2.8	64
169	Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. British Journal of Cancer, 1997, 75, 417-422.	6.4	63
170	Prognostic Value of Health-Related Quality-of-Life Data in Predicting Survival in Patients With Anaplastic Oligodendrogliomas, From a Phase III EORTC Brain Cancer Group Study. Journal of Clinical Oncology, 2007, 25, 5731-5737.	1.6	63
171	First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. Neuro-Oncology, 2011, 13, 235-241.	1.2	60
172	Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro-Oncology, 2018, 20, 838-847.	1.2	60
173	Interlaboratory comparison of IDH mutation detection. Journal of Neuro-Oncology, 2013, 112, 173-178.	2.9	59
174	Urgent considerations for the neuro-oncologic treatment of patients with gliomas during the COVID-19 pandemic. Neuro-Oncology, 2020, 22, 912-917.	1.2	59
175	Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. Neuro-Oncology, 2021, 23, 1100-1112.	1.2	59
176	Negative sural nerve biopsy in neurolymphomatosis. Journal of Neurology, 1999, 246, 1159-1163.	3.6	58
177	EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. Neuro-Oncology, 2012, 14, 1503-1510.	1.2	58
178	Chemotherapy in glioma. CNS Oncology, 2015, 4, 179-192.	3.0	58
179	CODEL: phase III study of RT, RTâ€‰+ TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. Neuro-Oncology, 2021, 23, 457-467.	1.2	58
180	Pros and cons of current brain tumor imaging. Neuro-Oncology, 2014, 16, vii2-vii11.	1.2	56

#	Article	IF	Citations
181	Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. Neuro-Oncology, 2019, 21, 1587-1594.	1.2	56
182	EANOâ€"EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. Lancet Oncology, The, 2019, 20, e715-e728.	10.7	56
183	Cisplatin-induced encephalopathy and seizures. Anti-Cancer Drugs, 2003, 14, 443-446.	1.4	55
184	Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrixâ€"associated gene modules. Neuro-Oncology, 2013, 15, 1684-1695.	1.2	55
185	Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation - an International Primary Central Nervous System Lymphoma Study Group project. Haematologica, 2013, 98, 808-813.	3.5	55
186	Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clinical Cancer Research, 2017, 23, 5745-5756.	7.0	53
187	Management of low-grade glioma: a systematic review and meta-analysis. Neuro-Oncology Practice, 2019, 6, 249-258.	1.6	52
188	Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. The Lancet Digital Health, 2021, 3, e784-e794.	12.3	52
189	New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European Journal of Cancer, 2013, 49, 3477-3485.	2.8	51
190	Anaplastic Oligodendroglioma and Oligoastrocytoma. Neurologic Clinics, 2007, 25, 1089-1109.	1.8	50
191	Assessment methods and prevalence of cognitive dysfunction in patients with low-grade glioma: A systematic review. Journal of Rehabilitation Medicine, 2015, 47, 481-488.	1.1	50
192	Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncology, The, 2012, 13, e196-e204.	10.7	49
193	Low-Molecular Weight Caldesmon as a Potential Serum Marker for Glioma. Clinical Cancer Research, 2005, 11, 4388-4392.	7.0	48
194	Neurolymphomatosis Of the median nerve. Neurology, 1995, 45, 1403-1405.	1.1	46
195	Progression of paclitaxel-induced neuropathy following discontinuation of treatment. Muscle and Nerve, 1997, 20, 750-752.	2.2	46
196	Molecular targeted therapies and chemotherapy in malignant gliomas. Current Opinion in Oncology, 2007, 19, 598-605.	2.4	46
197	Diagnosis of neurolymphomatosis with FDG PET. Neurology, 2006, 67, 722-723.	1.1	45
198	Incidence of central nervous system involvement in chronic lymphocytic leukemia and outcome to treatment. Journal of Neurology, 2008, 255, 828-830.	3.6	45

#	Article	IF	Citations
199	Addition of serum-containing medium to cerebrospinal fluid prevents cellular loss over time. Journal of Neurology, 2011, 258, 1507-1512.	3.6	45
200	The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial. European Journal of Cancer, 2015, 51, 1321-1330.	2.8	45
201	Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy. Neuro-Oncology, 2017, 19, now194.	1.2	45
202	Genetic aberrations in oligodendroglial tumours: an analysis using comparative genomic hybridization (CGH). , 1999, 188, 282-288.		44
203	Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. Cancer, 2008, 112, 1337-1344.	4.1	44
204	Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study) Tj ETQq0 0 0 rgBT /Overlock 10	2.8	44
205	Prognostic value of Ki67 index in anaplastic oligodendroglial tumours â€“ a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Histopathology, 2012, 60, 885-894.	2.9	44
206	A basic review on systemic treatment options in WHO grade II-III gliomas. Cancer Treatment Reviews, 2021, 92, 102124.	7.7	44
207	Predictive and Prognostic Markers in Neuro-Oncology. Journal of Neuropathology and Experimental Neurology, 2007, 66, 1074-1081.	1.7	42
208	PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Acta Neuropathologica Communications, 2015, 3, 88.	5.2	42
209	Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncology, The, 2018, 19, e33-e42.	10.7	42
210	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro-Oncology, 2014, 16, vii36-vii47.	1.2	41
211	Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro-Oncology, 2018, 20, 897-906.	1.2	41
212	Peri-ictal pseudoprogression in patients with brain tumor. Neuro-Oncology, 2011, 13, 775-782.	1.2	38
213	Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics. Acta Neuropathologica Communications, 2018, 6, 126.	5.2	38
214	Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. Neuro-Oncology, 2020, 22, 1568-1579.	1.2	38
215	Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC) Tj ETQq1 1 0.784314 rgBT /Overlock	44	38
216	Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. Neuro-Oncology, 2022, 24, 855-871.	1.2	38

#	Article	IF	Citations
217	Spinal epidural abscess complicating chronic epidural analgesia in 11 cancer patients: clinical findings and magnetic resonance imaging. Journal of Neurology, 1999, 246, 815-820.	3.6	37
218	European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Annals of Oncology, 2003, 14, 1732-1734.	1.2	36
219	Chemotherapy for low-grade glioma. Current Opinion in Neurology, 2015, 28, 633-938.	3.6	36
220	Treatment of secondary central nervous system lymphoma with intrathecal rituximab, highâ€dose methotrexate, and Râ€DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study. Hematological Oncology, 2017, 35, 497-503.	1.7	36
221	Barriers to accrual and enrollment in brain tumor trials. Neuro-Oncology, 2019, 21, 1100-1117.	1.2	36
222	Association Between Supratotal Glioblastoma Resection and Patient Survival: A Systematic Review and Meta-Analysis. World Neurosurgery, 2019, 127, 617-624.e2.	1.3	36
223	Firstâ€line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid. Epilepsia, 2021, 62, 1119-1129.	5.1	36
224	The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor. Journal of Neuro-Oncology, 1998, 37, 1-8.	2.9	35
225	Neurocognitive Functions and Quality of Life in Haematological Patients Receiving Haematopoietic Stem Cell Grafts: A One-Year Follow-Up Pilot Study. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 283-293.	1.3	35
226	Does early resection of presumed low-grade glioma improve survival? A clinical perspective. Journal of Neuro-Oncology, 2017, 133, 137-146.	2.9	35
227	Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?. Neuro-Oncology, 2019, 21, 1447-1457.	1.2	35
228	Dose-dense cisplatin/paclitaxel. European Journal of Cancer, 2002, 38, 2005-2013.	2.8	34
229	Diagnosis and management of oligodendroglioma. Seminars in Oncology, 2004, 31, 645-652.	2.2	34
230	Dose dense 1Âweek on/1Âweek off temozolomide in recurrent glioma: a retrospective study. Journal of Neuro-Oncology, 2012, 108, 195-200.	2.9	34
231	DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells. Cancer Letters, 2015, 356, 525-535.	7.2	34
232	Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumabâ€”a report from the BELOB trial. Neuro-Oncology, 2017, 19, 853-861.	1.2	34
233	Fatigue in patients with low grade glioma: systematic evaluation of assessment and prevalence. Journal of Neuro-Oncology, 2017, 133, 237-246.	2.9	34
234	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. Neuro-Oncology, 2021, 23, 1547-1559.	1.2	34

#	Article	IF	Citations
235	Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning. Neuro-Oncology, 2023, 25, 279-289.	1.2	34
236	Assessment of pre-treatment cognitive performance in adult bone marrow or haematopoietic stem cell transplantation patients: A comparative study. European Journal of Cancer, 2005, 41, 1007-1016.	2.8	33
237	Lhermitte's sign following chemotherapy with docetaxel. Neurology, 1998, 50, 563-564.	1.1	32
238	Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity. European Journal of Cancer, 2002, 38, 387-391.	2.8	32
239	B and T cell imbalances in CSF of patients with Hu-antibody associated PNS. Journal of Neuroimmunology, 2008, 195, 164-170.	2.3	32
240	Human chorionic gonadotropin treatment of anti-Hu-associated paraneoplastic neurologicalsyndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1341-1344.	1.9	32
241	Alphaâ€internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. Cancer, 2011, 117, 3014-3026.	4.1	32
242	Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Annals of Oncology, 2011, 22, 2144-2149.	1.2	32
243	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathologica, 2021, 141, 945-957.	7.7	32
244	The diagnosis and management of brain metastases. Current Opinion in Neurology, 2001, 14, 717-723.	3.6	31
245	Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers. Annals of Oncology, 2008, 19, vii209-vii216.	1.2	31
246	Current treatment of low grade gliomas. Memo - Magazine of European Medical Oncology, 2012, 5, 223-227.	0.5	31
247	Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics. Journal of Neuro-Oncology, 2015, 121, 365-372.	2.9	31
248	Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review. Lancet Oncology, The, 2018, 19, e407-e418.	10.7	31
249	Grade II and III Oligodendroglioma and Astrocytoma. Neurologic Clinics, 2018, 36, 467-484.	1.8	31
250	Deafness, sensory neuropathy, and ovarian dysgenesis: A new syndrome or a broader spectrum of Perrault syndrome?. American Journal of Medical Genetics Part A, 1994, 51, 81-82.	2.4	30
251	Advances in the biology and treatment of oligodendrogliomas. Current Opinion in Neurology, 2004, 17, 675-680.	3.6	30
252	Case-referent comparison of cognitive functions in patients receiving haematopoietic stem-cell transplantation for haematological malignancies: Two-year follow-up results. European Journal of Cancer, 2007, 43, 2052-2059.	2.8	30

#	Article	IF	Citations
253	Toward a standard pathological and molecular characterization of recurrent glioma in adults: a Response Assessment in Neuro-Oncology effort. Neuro-Oncology, 2020, 22, 450-456.	1.2	30
254	Chromosome 1p loss evaluation in anaplastic oligodendrogliomas. Neuropathology, 2008, 28, 440-443.	1.2	29
255	Primary central nervous system lymphoma in the elderly: a multicentre retrospective analysis. British Journal of Haematology, 2010, 151, 179-184.	2.5	29
256	Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. Journal of Clinical Oncology, 2004, 22, 2-2.	1.6	29
257	A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma. Clinical Cancer Research, 2022, 28, 452-460.	7.0	29
258	Intracranial granulocytic sarcoma (chloroma) may mimic a subdural hematoma. Journal of Neurology, 2005, 252, 498-499.	3.6	28
259	The CASPR2 cell adhesion molecule functions as a tumor suppressor gene in glioma. Oncogene, 2010, 29, 6138-6148.	5.9	28
260	Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. European Journal of Cancer, 2018, 94, 168-178.	2.8	28
261	Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034. Journal of Clinical Oncology, 2007, 25, 2005-2005.	1.6	28
262	Molecular subtypes of glioma identified by genomeâ€wide methylation profiling. Genes Chromosomes and Cancer, 2013, 52, 665-674.	2.8	27
263	Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines*. Neuro-Oncology, 2019, 21, 424-427.	1.2	27
264	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. Clinical Cancer Research, 2022, 28, 2527-2535.	7.0	27
265	Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline. Journal of Clinical Oncology, 2022, 40, 2271-2276.	1.6	27
266	Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma. Future Oncology, 2010, 6, 1691-1710.	2.4	26
267	Low-grade and anaplastic oligodendroglioma. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 361-380.	1.8	26
268	Withdrawal of antiepileptic drugs in patients with low grade and anaplastic glioma after long-term seizure freedom: a prospective observational study. Journal of Neuro-Oncology, 2019, 142, 463-470.	2.9	26
269	A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. Journal of Neuro-Oncology, 2020, 146, 79-89.	2.9	26
270	Integrated genomic profiling identifies candidate genes implicated in gliomaâ€genesis and a novel LEO1â€SLC12A1 fusion gene. Genes Chromosomes and Cancer, 2010, 49, 509-517.	2.8	25

#	Article	IF	Citations
271	MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. Journal of Neuro-Oncology, 2011, 101, 405-417.	2.9	25
272	Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033. Neuro-Oncology, 2021, 23, 803-811.	1.2	25
273	Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. Archives of Pathology and Laboratory Medicine, 2022, 146, 547-574.	2.5	25
274	The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration. Journal of Neuro-Oncology, 1999, 42, 117-122.	2.9	24
275	Surgical resection improves outcome in metastatic epidural spinal cord compression. Lancet, The, 2005, 366, 609-610.	13.7	24
276	Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma. Journal of Neuro-Oncology, 2018, 139, 349-357.	2.9	24
277	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. Journal of Neuro-Oncology, 2019, 144, 205-210.	2.9	24
278	Evaluation of the Hippocampal Normal Tissue Complication Model in a Prospective Cohort of Low Grade Glioma Patientsâ€"An Analysis Within the EORTC 22033 Clinical Trial. Frontiers in Oncology, 2019, 9, 991.	2.8	24
279	Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma. Clinical Cancer Research, 2019, 25, 3259-3265.	7.0	24
280	Adolescents and Young Adults Living With an Uncertain or Poor Cancer Prognosis: The â€œNewâ€•Lost Tribe. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 240-246.	4.9	24
281	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro-Oncology, 2020, 22, 601-612.	1.2	23
282	The incidence of pseudo-progression in a cohort of malignant glioma patients treated with chemo-radiation with temozolomide. Journal of Clinical Oncology, 2007, 25, 2009-2009.	1.6	23
283	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. Journal of Clinical Oncology, 2022, 40, 2539-2545.	1.6	23
284	Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration. European Journal of Cancer, 1995, 31, 678-681.	2.8	22
285	The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. European Journal of Cancer, 2019, 116, 190-198.	2.8	22
286	On highâ€risk, lowâ€grade glioma: What distinguishes high from low?. Cancer, 2019, 125, 174-176.	4.1	22
287	The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma. Frontiers in Oncology, 2020, 10, 1087.	2.8	22
288	Cerebral venous and sinus thrombosis with cerebrospinal fluid circulation block after the first methotrexate administration by lumbar puncture. Neuroradiology, 2002, 44, 929-932.	2.2	21

#	Article	IF	Citations
289	Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Journal of Neuro-Oncology, 2011, 103, 221-230.	2.9	21
290	Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 Trials. Journal of Clinical Oncology, 2015, 33, 1943-1950.	1.6	21
291	Joint modeling of longitudinal health-related quality of life data and survival. Quality of Life Research, 2015, 24, 795-804.	3.1	21
292	New perspectives for the diagnosis and treatment of oligodendroglioma. Expert Review of Anticancer Therapy, 2001, 1, 348-356.	2.4	20
293	A solitary spinal cord toxoplasma lesion after peripheral stem-cell transplantation. Journal of Neurology, 2001, 248, 814-815.	3.6	20
294	A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.2	20
295	Defining EGFR amplification status for clinical trial inclusion. Neuro-Oncology, 2019, 21, 1263-1272.	1.2	20
296	ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600Eâ€“MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG). Neuro-Oncology, 2019, 21, vi19-vi20.	1.2	20
297	Prevention of Chemotherapy-Induced Neuropathy: Leukemia Inhibitory Factor. Clinical Cancer Research, 2005, 11, 1691-1693.	7.0	19
298	A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab. Molecular Oncology, 2016, 10, 1296-1304.	4.6	19
299	Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. Cancer Medicine, 2020, 9, 8373-8385.	2.8	19
300	Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. Radiology, 2020, 297, 164-175.	7.3	19
301	Determining medical decision-making capacity in brain tumor patients: why and how?. Neuro-Oncology Practice, 2020, 7, 599-612.	1.6	19
302	Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD).. Journal of Clinical Oncology, 2012, 30, 2-2.	1.6	19
303	ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Nonâ€“Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. Clinical Cancer Research, 2022, 28, 2506-2516.	7.0	19
304	Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel. Anti-Cancer Drugs, 1998, 9, 759-764.	1.4	18
305	Repeatability and reproducibility of relative cerebral blood volume measurement of recurrent glioma in a multicentre trial setting. European Journal of Cancer, 2019, 114, 89-96.	2.8	18
306	INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS. Neuro-Oncology, 2019, 21, vi137-vi137.	1.2	18

#	Article	IF	Citations
307	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort. Neuro-Oncology, 2022, 24, 1726-1735.	1.2	18
308	Hemangioblastomatosis in a patient with von Hippel-Lindau disease. Journal of Neuro-Oncology, 2007, 82, 163-164.	2.9	17
309	Gene expression profiles of gliomas in formalin-fixed paraffin-embedded material. British Journal of Cancer, 2012, 106, 538-545.	6.4	17
310	ATCT-16CODEL (ALLIANCE-N0577; EORTC-26081/2208; NRG-1071; NCIC-CEC-2): PHASE III RANDOMIZED STUDY OF RT VS. RT + TMZ VS. TMZ FOR NEWLY DIAGNOSED 1p/19q-CODELETED ANAPLASTIC GLIOMA. ANALYSIS OF PATIENTS TREATED ON THE ORIGINAL PROTOCOL DESIGN. Neuro-Oncology, 2015, 17, v4.4-v5.	1.2	17
311	Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies. Seminars in Oncology, 2003, 30, 39-44.	2.2	16
312	Current and Future Trials of the EORTC Brain Tumor Group. Oncology Research and Treatment, 2004, 27, 246-250.	1.2	16
313	Severe Amnesia due to HHV-6 Encephalitis after Allogenic Stem Cell Transplantation. European Neurology, 2005, 54, 233-234.	1.4	16
314	Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial. British Journal of Cancer, 2015, 113, 226-231.	6.4	16
315	Prevalence of changes in personality and behavior in adult glioma patients: a systematic review. Neuro-Oncology Practice, 2016, 3, 222-231.	1.6	16
316	The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy. European Journal of Cancer, 2021, 156, 93-108.	2.8	16
317	The many challenges of treating elderly glioblastoma patients. Nature Reviews Neurology, 2015, 11, 374-375.	10.1	15
318	Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial â€œconcurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic gliomaâ€• Individual case review analysis. Radiotherapy and Oncology, 2018, 127, 292-298.	0.6	15
319	Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients. Neuro-Oncology, 2021, 23, 1327-1336.	1.2	15
320	Increased levels of soluble CD27 in the cerebrospinal fluid are not diagnostic for leptomeningeal involvement by lymphoid malignancies. Annals of Hematology, 2002, 81, 187-191.	1.8	14
321	ACTR-39. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE. Neuro-Oncology, 2019, 21, vi21-vi22.	1.2	14
322	Detection of Aneuploidy in Cerebrospinal Fluid from Patients with Breast Cancer Can Improve Diagnosis of Leptomeningeal Metastases. Clinical Cancer Research, 2021, 27, 2798-2806.	7.0	14
323	Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.. Journal of Clinical Oncology, 2016, 34, 2019-2019.	1.6	14
324	Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer. British Journal of Cancer, 2003, 88, 814-821.	6.4	13

#	Article	IF	Citations
325	RTOG 9802: Good Wines Need Aging. Journal of Clinical Oncology, 2013, 31, 653-654.	1.6	13
326	Response Assessment in Neuro-Oncology (RANO): more than imaging criteria for malignant glioma. Neuro-Oncology Practice, 2015, 2, 205-209.	1.6	13
327	Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation. Frontiers in Oncology, 2020, 10, 596.	2.8	13
328	Mapping tumour heterogeneity with pulsed 3D CEST MRI in non-enhancing glioma at 3ÂT. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2022, 35, 53-62.	2.0	13
329	The Erasmus Glioma Database (EGD): Structural MRI scans, WHO 2016 subtypes, and segmentations of 774 patients with glioma. Data in Brief, 2021, 37, 107191.	1.0	13
330	Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus chemoirradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter.. Journal of Clinical Oncology, 2014, 32, 2003-2003.	1.6	13
331	A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM).. Journal of Clinical Oncology, 2014, 32, 2021-2021.	1.6	13
332	Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer. British Journal of Cancer, 1996, 73, 1265-1267.	6.4	12
333	Management of metastatic (parenchymal, leptomeningeal, and epidural) lesions. Current Opinion in Oncology, 2004, 16, 309-313.	2.4	12
334	Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials. European Journal of Cancer, 2021, 144, 162-168.	2.8	12
335	Effect of antiepileptic drugs in glioma patients on self-reported depression, anxiety, and cognitive complaints. Journal of Neuro-Oncology, 2021, 153, 89-98.	2.9	12
336	^{99m} Tcâ€SPECT in the diagnosis of skull base metastasis. Neurology, 1997, 48, 1326-1330.	1.1	12
337	Clinical course and risk factors of neurotoxicity following cisplatin in an intensive dosing schedule. European Journal of Neurology, 1994, 1, 45-50.	3.3	11
338	Glial fibrillary acidic protein and its fragments discriminate astrocytoma from oligodendroglioma. Electrophoresis, 1999, 20, 1087-1091.	2.4	11
339	Adjuvant treatment of high grade gliomas. Annals of Oncology, 2006, 17, x186-x190.	1.2	11
340	Are we done with dose-intense temozolomide in recurrent glioblastoma?. Neuro-Oncology, 2014, 16, 1161-1163.	1.2	11
341	Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials. Neuro-Oncology, 2021, 23, 189-198.	1.2	11
342	The relationship between mental fatigue, cognitive functioning, and employment status in patients with low-grade glioma: a cross-sectional single-center study. Disability and Rehabilitation, 2022, 44, 7413-7419.	1.8	11

#	Article	IF	Citations
343	A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 1997, 40, 347-352.	2.3	10
344	Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas. European Journal of Cancer, 1998, 34, 1570-1574.	2.8	10
345	Phase II study of weekly dose-intensified cisplatin chemotherapy with oral etoposide in recurrent glioma. Journal of Neuro-Oncology, 1999, 44, 59-64.	2.9	10
346	Withdrawal of antiepileptic drugs in glioma patients after long-term seizure freedom: design of a prospective observational study. BMC Neurology, 2014, 14, 157.	1.8	10
347	Novel methods to diagnose leptomeningeal metastases in breast cancer. Neuro-Oncology, 2019, 21, 428-439.	1.2	10
348	Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. European Journal of Cancer, 2021, 147, 1-12.	2.8	10
349	Prescription preferences of antiepileptic drugs in brain tumor patients: An international survey among EANO members. Neuro-Oncology Practice, 2022, 9, 105-113.	1.6	10
350	Intratumoral Distribution of 1p Loss in Oligodendroglial Tumors. Journal of Neuropathology and Experimental Neurology, 2007, 66, 1118-1123.	1.7	9
351	No evidence for the presence of HuD-specific T cells in the cerebrospinal fluid of patients with Huassociated paraneoplastic neurological syndromes. Journal of Neurology, 2009, 256, 279-282.	3.6	9
352	Flow cytometry shows added value in diagnosing lymphoma in brain biopsies. Cytometry Part B - Clinical Cytometry, 2018, 94, 928-934.	1.5	9
353	Differences in spatial distribution between WHO 2016 low-grade glioma molecular subgroups. Neuro-Oncology Advances, 2019, 1, vdz001.	0.7	9
354	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. Neurology, 2019, 92, e2754-e2763.	1.1	9
355	EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand. Neuro-Oncology Advances, 2020, 2, vdz051.	0.7	9
356	Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. Neuro-Oncology, 2020, 22, 1667-1676.	1.2	9
357	Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial. Neuro-Oncology, 2021, 23, 1315-1326.	1.2	9
358	The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide. Journal of Neuro-Oncology, 2021, 154, 73-81.	2.9	9
359	Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial.. Journal of Clinical Oncology, 2017, 35, 2003-2003.	1.6	9
360	Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. Neuro-Oncology, 2022, 24, 1219-1229.	1.2	9

#	Article	IF	Citations
361	Prolonged remission of primary central nervous system lymphoma after discontinuation of steroid therapy. Journal of Neuro-Oncology, 1992, 13, 257-259.	2.9	8
362	Erythropoietin induced visual hallucinations after bone marrow transplantation. Journal of Neurology, 1999, 246, 614-616.	3.6	8
363	PCV chemotherapy for recurrent glioblastoma multiforme. Neurology, 2001, 56, 1782-1782.	1.1	8
364	Long-term employment status and the association with fatigue in patients with grade II glioma. Journal of Rehabilitation Medicine, 2021, 53, jrm00198.	1.1	8
365	MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma. Journal of Neuro-Oncology, 2021, 152, 357-362.	2.9	8
366	Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion.. Journal of Clinical Oncology, 2017, 35, 2009-2009.	1.6	8
367	Noninvasive differentiation of molecular subtypes of adult nonenhancing glioma using MRI perfusion and diffusion parameters. Neuro-Oncology Advances, 2022, 4, vdac023.	0.7	8
368	Acute painful lumbosacral paresthesia after intrathecal rituximab. Journal of Neurology, 2012, 259, 559-561.	3.6	7
369	Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma. Neuro-Oncology Practice, 2019, 6, 17-21.	1.6	7
370	The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis. Neuro-Oncology, 2022, 24, 429-441.	1.2	7
371	Extent of radiological response does not reflect survival in primary central nervous system lymphoma. Neuro-Oncology Advances, 2021, 3, vdab007.	0.7	7
372	Development and external validation of a clinical prediction model for survival in patients with IDH wild-type glioblastoma. Journal of Neurosurgery, 2022, 137, 914-923.	1.6	7
373	Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period. Neuro-Oncology, 2022, 24, 2159-2169.	1.2	7
374	Prognostic validation and refinement of a classification system for extent of resection in glioblastoma: A report of the RANO resect group.. Journal of Clinical Oncology, 2022, 40, 2003-2003.	1.6	7
375	EBV related cerebral lymphoma in a leukemia patient treated with alemtuzumab. Journal of Neurology, 2011, 258, 944-945.	3.6	6
376	Efficacy of intrathecal chemotherapy in patients with central nervous system involvement of hematological malignancies: a retrospective analysis. Journal of Neuro-Oncology, 2018, 139, 117-123.	2.9	6
377	Gray Areas in the Gray Matter: IDH1/2 Mutations in Glioma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 96-103.	3.8	6
378	Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms. Hematology/Oncology Clinics of North America, 2021, 36, 95-111.	2.2	6

#	Article	IF	Citations
379	Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD).. Journal of Clinical Oncology, 2012, 30, 2-2.	1.6	6
380	DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcomeâ€"including in elderly patients. Acta Neuropathologica Communications, 2022, 10, 39.	5.2	6
381	The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: a systematic review. Neuro-Oncology Advances, 2022, 4, .	0.7	6
382	Resolution of EBV+ CNS lymphoma with appearance of CSF EBV-specific T cells. Annals of Neurology, 2005, 58, 788-792.	5.3	5
383	Evidence-based management of adult patients with diffuse glioma â€“ Authors' reply. Lancet Oncology, The, 2017, 18, e430-e431.	10.7	5
384	Precision Medicine for Primary Central Nervous System Tumors: Are We There Yet?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 158-167.	3.8	5
385	Timing of radiotherapy in newly diagnosed glioblastoma: no need to rush?. Neuro-Oncology, 2018, 20, 868-869.	1.2	5
386	ACTR-11. SECOND INTERIM AND 1ST MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CODELETION. Neuro-Oncology, 2019, 21, vi14-vi14.	1.2	5
387	Comprehensive Assessment of Incidence, Risk Factors, and Mechanisms of Impaired Medical and Psychosocial Health Outcomes among Adolescents and Young Adults with Cancer: Protocol of the Prospective Observational COMPRAYA Cohort Study. Cancers, 2021, 13, 2348.	3.7	5
388	Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study. Annals of Oncology, 2020, 31, 1046-1055.	1.2	5
389	Patients with primary brain tumors and COVID-19: A report from the Dutch Oncology COVID-19 Consortium. Neuro-Oncology, 2022, 24, 326-328.	1.2	5
390	MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas. Neuro-Oncology, 2022, 24, 665-667.	1.2	5
391	Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas. Neuro-Oncology, 2022, 24, 1035-1047.	1.2	5
392	A qualitative study on the challenges health care professionals face when caring for adolescents and young adults with an uncertain and/or poor cancer prognosis. ESMO Open, 2022, 7, 100476.	4.5	5
393	The management of cerebral metastasis from germ cell cancer; walking the tightrope. European Journal of Cancer, 2008, 44, 1622-1624.	2.8	4
394	Anaplastic oligodendroglial tumors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 105, 467-484.	1.8	4
395	Clinical Neuropathology Practice News 2-2013: immunohistochemistry pins IDH in glioma Â– molecular testing procedures under scrutiny. , 2013, 32, 82-83.		4
396	Facing the Future of Brain Tumor Clinical Research. Clinical Cancer Research, 2014, 20, 5591-5600.	7.0	4

#	Article	IF	Citations
397	Oligodendrogliomas: a short history of clinical developments. CNS Oncology, 2015, 4, 281-285.	3.0	4
398	Assessment of imaging biomarkers in the follow-up of brain metastases after SRS. Neuro-Oncology, 2021, 23, 1983-1984.	1.2	4
399	Phosphorus-31 Chemical Shift Imaging of Metastatic Tumors Located in the Spine Region. Investigative Radiology, 1997, 32, 344-350.	6.2	4
400	Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. Neuro-Oncology, 2022, 24, 331-357.	1.2	4
401	Effect of an ACTH(4â€“9) analogue on cisplatin neuropathy of longstanding duration: a phase II study. Clinical Neurology and Neurosurgery, 1995, 97, 139-141.	1.4	3
402	Bevacizumab alone or in combination with chemotherapy in glioblastomas?â€“Authors' reply. Lancet Oncology, The, 2014, 15, e473-e474.	10.7	3
403	How I treat anaplastic glioma without 1p/19q codeletion. ESMO Open, 2019, 4, e000534.	4.5	3
404	The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. Neuro-Oncology Advances, 2021, 3, vdab035.	0.7	3
405	Hypermutated recurrences: Identifying the clinical relevance. Neuro-Oncology, 2021, 23, 1805-1806.	1.2	3
406	CTNI-29. CODEL: PHASE III TRIAL OF RT ALONE, RT PLUS TMZ, OR TMZ ALONE FOR NEWLY-DIAGNOSED, 1p/19q CODELETED ANAPLASTIC OLIGODENDROGLIOMA. ANALYSIS FROM THE INITIAL STUDY DESIGN. (NCCTG N0577,)	1.2	3
407	Clinical prognostic factors affecting survival in patients with newly diagnosed Glioblastoma Multiforme (GBM). Journal of Clinical Oncology, 2004, 22, 9599-9599.	1.6	3
408	Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial. Clinical Cancer Research, 2022, 28, 2440-2448.	7.0	3
409	The European organisation for research and treatment of cancer strategy for new drug development in brain tumors. Seminars in Oncology, 2003, 30, 77-80.	2.2	2
410	Neurogenic pulmonary oedema in a patient with leptomeningeal carcinomatosis. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1097-1097.	1.9	2
411	P09.06â€,Withdrawal of antiepileptic drugs in glioma patients after long-term seizure freedom. Neuro-Oncology, 2016, 18, iv61-iv61.	1.2	2
412	Gene-Tailored Treatments for Brain Disorders: Challenges and Opportunities. Public Health Genomics, 2016, 19, 170-177.	1.0	2
413	Radiogenomic classification of the 1p/19q status in presumed low-grade gliomas. , 2017, , .		2
414	LTBK-12. EORTC 26951, RANDOMIZED STUDY OF ADJUVANT PCV AFTER 59.4 GY RADIOTHERAPY: VERY LONG TERM FOLLOW-UP. Neuro-Oncology, 2019, 21, vi285-vi285.	1.2	2

#	Article	IF	Citations
415	Treatment of anaplastic gliomas. Current Opinion in Oncology, 2021, Publish Ahead of Print, 621-625.	2.4	2
416	EMG before and after cervical anterior discectomy. Acta Neurologica Scandinavica, 1995, 92, 332-336.	2.1	1
417	Increased rCBV in status epilepticus. Journal of Neurology, 2012, 259, 1746-1748.	3.6	1
418	Low-Grade Gliomas. , 2016, , 452-468.e3.		1
419	Varicella zoster virus encephalitis in a patient with a solid carcinoma: a case report. Journal of Neurology, 2017, 264, 1281-1283.	3.6	1
420	NCOG-05. IMPACT OF ADDITIONAL RITUXIMAB TO STANDARD THERAPY ON COGNITIVE PERFORMANCES IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS. Neuro-Oncology, 2019, 21, vi159-vi159.	1.2	1
421	QOLP-03. MEASURING CHANGE IN HEALTH-RELATED QUALITY OF LIFE: THE ADDED VALUE OF ANALYSIS ON THE INDIVIDUAL PATIENT LEVEL IN GLIOMA PATIENTS IN CLINICAL DECISION MAKING. Neuro-Oncology, 2019, 21, vi197-vi198.	1.2	1
422	Pleural metastasis of anaplastic meningioma. Radiology Case Reports, 2020, 15, 2668-2671.	0.6	1
423	Response to Letter to Editor. Neuro-Oncology, 2020, 22, 1706-1707.	1.2	1
424	Gender issues from the perspective of health-care professionals in Neuro-oncology: an EANO and EORTC Brain Tumor Group survey. Neuro-Oncology Practice, 2020, 7, 249-259.	1.6	1
425	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma â€“ Authors' reply. Lancet Oncology, The, 2021, 22, e346.	10.7	1
426	Optimizing the identification of anaplastic oligodendroglioma patients that benefit from adjuvant PCV chemotherapy using the Illumina platform: A further report from EORTC study 26951.. Journal of Clinical Oncology, 2013, 31, 2011-2011.	1.6	1
427	Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling. Neuro-Oncology Advances, 2020, 2, vdaa147.	0.7	1
428	The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncology Advances, 2022, 4, vdac032.	0.7	1
429	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. Neuro-Oncology, 2022, 24, 358-383.	1.2	1
430	Subacute neurological deficits and respiratory insufficiency due to intrathecal methotrexate.. Journal of Clinical and Translational Research, 2021, 7, 809-810.	0.3	1
431	Early or delayed radiotherapy for low-grade glioma? â€“ Authors' reply. Lancet Oncology, The, 2005, 6, 922.	10.7	0
432	Treatment of newly diagnosed anaplastic gliomas. European Journal of Cancer, Supplement, 2007, 5, 409-410.	2.2	0

#	Article	IF	Citations
433	A 40-YEAR-OLD WOMAN WITH A PROGRESSIVE PERIVENTRICULAR WHITE MATTER LESION. Brain Pathology, 2008, 18, 103-104.	4.1	0
434	Reply to P. Farace et al. Journal of Clinical Oncology, 2011, 29, e149-e149.	1.6	0
435	Reply to A.A. Brandes et al. Journal of Clinical Oncology, 2011, 29, e247-e247.	1.6	0
436	EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology. European Journal of Cancer, Supplement, 2012, 10, 20-26.	2.2	0
437	AT-34CONSTRUCTION OF AN INTEGRATED DIAGNOSTIC ALGORITHM CONSISTING OF CONSENSUS HISTOLOGIC AND MOLECULAR PARAMETERS OF TWO EORTC TRIALS ON ANAPLASTIC GLIOMA. Neuro-Oncology, 2014, 16, v16-v16.	1.2	0
438	Reply to M.C. Chamberlain. Journal of Clinical Oncology, 2014, 32, 2273-2274.	1.6	0
439	NIMG-01. DIFFUSION MRI PHENOTYPES PREDICT OVERALL SURVIVAL BENEFIT FROM ANTI-VEGF MONOTHERAPY IN GLIOBLASTOMA AT FIRST OR SECOND RELAPSE. Neuro-Oncology, 2017, 19, vi142-vi143.	1.2	0
440	NIMG-19. GLIOMA-LIKE INTRAPARENCHYMATOUS LESIONS ON MRI BRAIN IN ADULT NEUROFIBROMATOSIS TYPE 1 PATIENTS. Neuro-Oncology, 2017, 19, vi146-vi146.	1.2	0
441	Preface. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 149, ix.	1.8	0
442	OS3.1 Antiepileptic drugs and their association with depression, anxiety and subjective cognitive impairment in glioma patients. Neuro-Oncology, 2019, 21, iii8-iii8.	1.2	0
443	OS3.5 Prescription medications in glioma patients and the prevalence of depression, anxiety and subjective cognitive impairment. Neuro-Oncology, 2019, 21, iii9-iii9.	1.2	0
444	SURG-30. CLINICAL COURSE OF IDH-MUTATED LOW-GRADE GLIOMAS DURING THE POSTSURGICAL ACTIVE MONITORING PHASE: ASYMPTOMATIC PATIENTS, WELL CONTROLLED SEIZURES, BUT CONTINUOUS GROWTH OF TUMOR RESIDUES. Neuro-Oncology, 2019, 21, vi245-vi246.	1.2	0
445	QOLP-04. CALCULATING THE NET CLINICAL BENEFIT IN BRAIN TUMOR TRIALS BY COMBINING SURVIVAL AND HEALTH-RELATED QUALITY OF LIFE DATA USING TWO METHODS: QUALITY ADJUSTED SURVIVAL EFFECT SIZES AND JOINT MODELLING. Neuro-Oncology, 2019, 21, vi198-vi198.	1.2	0
446	P14.41 Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC-26101 trial. Neuro-Oncology, 2019, 21, iii76-iii76.	1.2	0
447	Quantification of leptomeningeal metastases from solid tumors remains a challenging issue. Neuro-Oncology, 2020, 22, 592-593.	1.2	0
448	Fast-growing oligodendrogliomas are aggressive tumorsâ€"the real life biomarker?. Neuro-Oncology, 2020, 22, 907-908.	1.2	0
449	Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez. Neuro-Oncology, 2021, 23, 506-507.	1.2	0
450	Prognostic factors in leptomeningeal metastases. Neuro-Oncology, 2021, 23, 1208-1209.	1.2	0

#	Article	IF	Citations
451	Panel review of a set of anaplastic oligodendroglioma of EORTC trial 26951: interobserver variation, correlation with 1p/19q loss and clinical outcome. FASEB Journal, 2007, 21, A26.	0.5	0
452	Anaplastic Oligodendrogliomas and Mixed Gliomas. , 2011, , 233-248.		0
453	Tumoren van het zenuwstelsel. , 2011, , 501-512.		0
454	How to Use Molecular Markers When Caring for a Patient with Brain Cancer: 1P/19Q as a Predictive and Prognostic Marker in the Neuro-oncology Clinic. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 114-116.	3.8	0
455	Leptomeningeal metastases: A rano proposal for response criteria.. Journal of Clinical Oncology, 2014, 32, e13019-e13019.	1.6	0
456	Joint modeling of longitudinal health-related quality of life (HRQoL) data and survival.. Journal of Clinical Oncology, 2014, 32, 2034-2034.	1.6	0
457	Tumoren van het zenuwstelsel. , 2017, , 499-512.		0
458	How to Use Molecular Markers When Caring for a Patient with Brain Cancer: 1P/19Q as a Predictive and Prognostic Marker in the Neuro-oncology Clinic. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 114-116.	3.8	0